Use of Imaging Markers by Fluorocholine PET/MR to Predict Molecular Subtypes and Clinical Outcomes of Breast Cancer: a Pilot Study

What this Trial Is About

Researchers are studying breast cancer in women aged 25 to 75 using advanced imaging techniques to better understand how certain imaging markers relate to breast cancer types, treatment responses, and patient outcomes. The study aims to determine which imaging features are most accurate for predicting these clinical aspects. This observational research focuses on pre-treatment imaging and its association with cancer characteristics and prognosis. Participants will undergo two types of imaging scans before treatment: a whole body PET/MR scan with a tracer called FDG and a breast-specific PET/MR scan using a tracer called 18F-Fluorocholine (FCH). These scans are performed on separate days with at least a two-day interval. The breast scan includes the use of MRI contrast dye during the procedure. Medical imaging experts will analyze the results and share findings with the patients' doctors to aid clinical decisions. During the study, participants will fast for at least six hours before imaging. The research team will monitor imaging markers linked to breast cancer subtypes and clinical factors like tissue grade and prognosis. The main outcome is the relationship between FCH PET/MR imaging and cancer types, assessed over at least 40 weeks from enrollment. Secondary outcomes include links to prognosis and treatment responses. Radiation exposure from the imaging is low and comparable to a chest CT scan. Participants' safety and ongoing medical care will be supported throughout the study.

Fluorocholine PET/MR in Breast Cancer